Announcements
US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors
Date – Jan. 2, 2023
Datar Cancer Genetics now has three Breakthrough Designations granted by the USFDA, including liquid biopsies for breast and prostate cancer detection.
'Game Changer' Blood Test Detects Breast Cancer
Date – July 24, 2022
‘Game-changer’ blood test detects breast cancer earlier than X-rays, study shows.
Landmark Liquid Biopsy Study
Date – July 13, 2022
Landmark Liquid Biopsy Study Shows Accurate Detection of Early-Stage Breast Cancer.
The London Clinic
Date – April 11, 2022
Datar Cancer Genetics enters into partnership with The London Clinic to offer enhanced cancer testing services
FDA - Prostate Cancer
Date – February 14, 2022
Datar’s TriNetra-Prostate Blood Test Gets FDA Breakthrough Designation.
South Africa
Date – February 2, 2022
Groundbreaking high-sensitivity cancer screening test arriving in SA ahead of World Cancer Day.
Kuwait
Date – December 7, 2021
Virtus Group announces partnership with Datar Cancer Genetics for personalized precision oncology solutions in Kuwait.
FDA - Breast Cancer
Date – November 19, 2021
US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics.
The Healthcare Technology Report
Date – October 19, 2021
The Top 25 Women Leaders in Biotechnology of 2021 (Swati Deshpande – Datar Cancer Genetics)
NICE - UK
Date – July 13, 2021
UK – National Institute for Health and Care Excellence (NICE) issues MedTech Innovation Briefing on ‘Trublood-Prostate’ for Precision Non-Invasive Prostate Cancer Diagnosis Described by Experts as a ‘Game Changer’.
